Hanyok J J, MacNeil D J
Department of Cardiovascular Clinical Research, Bristol-Myers Squibb Company, Wallingford, CT 06492.
Cardiovasc Drugs Ther. 1990 Jun;4 Suppl 3:603-11. doi: 10.1007/BF00357038.
In two separate, double-blind, multicenter antiarrhythmic studies, sotalol was compared with propranolol or quinidine using placebo for baseline and/or washout periods. The comparison with quinidine was a crossover study. To be enrolled in these studies, patients were required to have a premature ventricular contraction (PVC) rate of at least 30/hr on a baseline 24-hour ambulatory ECG. At doses calculated to produce equivalent degrees of beta blockade, sotalol was more effective than propranolol in reducing the frequency of PVCs, and the two drugs produced similar reductions in ventricular tachycardia (VT) events. The side effects for sotalol and propranolol were mainly due to beta blockade, and the incidence of side effects with the two drugs was similar. Sotalol was comparable with quinidine in reducing PVCs and VT events. The side effects on sotalol were primarily related to beta-adrenergic blockade, while those on quinidine were predominantly gastrointestinal or neurologic in nature.
在两项独立的、双盲、多中心抗心律失常研究中，使用安慰剂作为基线期和/或洗脱期对照，将索他洛尔与普萘洛尔或奎尼丁进行比较。与奎尼丁的比较是一项交叉研究。要纳入这些研究，患者在基线24小时动态心电图上的室性早搏（PVC）发生率需至少为每小时30次。在计算产生等效程度β受体阻滞的剂量下，索他洛尔在降低PVC频率方面比普萘洛尔更有效，且两种药物在减少室性心动过速（VT）事件方面效果相似。索他洛尔和普萘洛尔的副作用主要是由于β受体阻滞，两种药物的副作用发生率相似。索他洛尔在降低PVC和VT事件方面与奎尼丁相当。索他洛尔的副作用主要与β肾上腺素能阻滞有关，而奎尼丁的副作用主要是胃肠道或神经系统方面的。
